COMISAIR Study Shows that CGM—Not the Insulin Delivery Method—Drives A1C Reduction
In this novel study, investigators examined not only the benefits of continuous glucose monitoring (CGM) augmented insulin therapy, they also looked at the impact of CGM separately in subjects on multiple daily injection (MDI) regimen vs. insulin pump therapy. Results from this year-long study challenged the notion that patients on MDI would not benefit as significantly from CGM use those on an insulin pump. Furthermore, this study presented convincing evidence that CGM – not the insulin delivery method – drives A1C reduction.
Source: Šoupal J, Petruželková L, Flekač M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
Related Content
Topics: Pregnancy, Accuracy, Safety Research Spotlight: “Accuracy and Safety of Dexcom G7 CGM Use in Pregnancy Patients with Diabetes” Polsky S, et al. Diabetes Technol Ther. 2024;26(5):307-12...
Title: Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes Topics: Long-Term Outcomes, Type 2 Diabetes, Noninsulin-Treated Research...